학술논문

Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children’s Oncology Group study
Document Type
Article
Source
In Blood Advances 12 March 2024 8(5):1116-1127
Subject
Clinical Trials and Observations
Language
ISSN
2473-9529